Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

NCT03013543 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03013543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 10, 2017
Completion date
March 1, 2022
Enrollment
213 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

genetic obesity, obesity, obesity due to melanocortin 4 receptor deficiency